Clinical trial
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In…
NCT00387127 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00387127 |
|---|---|
| Title | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer |
| Official title | A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Head and Neck |
| Intervention type | Drug |
| Interventions | Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy |
| Enrollment | 67 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jan 1, 2014 |
| First posted | Oct 12, 2006 |
| Last update posted | Jun 25, 2015 |
| Countries | Canada, France, Hungary, India, Netherlands, Peru, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: